Processa Pharmaceuticals, Inc.
PCSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $228 | $80 | $88 | $82 |
| - Cash | $6 | $7 | $3 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $222 | $73 | $85 | $81 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3 | -$4 | -$3 | -$3 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$4 | -$3 | -$3 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.75 | -6.25 | -7,438 | -19.5 |
| % Growth | 72% | 99.9% | -38,043.6% | – |
| Operating Cash Flow | -$3 | -$2 | -$3 | -$2 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | -$2 | -$3 | -$2 |